WallStreet Research Announces Availability of Corporate Profile Coverage on Pressure BioSciences Inc. (PBIO), Released at www.WallStreetResearch.org

NEW YORK, NY -- (Marketwired) -- 11/30/15 -- WallStreet Research", a top-ranked independent research firm with a history spanning over three decades, today announced that the firm has initiated corporate profile coverage on Pressure BioSciences, Inc. (OTCQB: PBIO). The analyst corporate profile report, together with additional information about WallStreet Research", is available at the www.WallStreetResearch.org website.

The corporate profile highlights the recent corporate strategy under the guidance of the company's management that includes CEO Mr. Richard T. Schumacher, the founder of the company. Mr. Schumacher has served as CEO and President of Pressure BioSciences since September 2004. Dr. Edmund Ting, Senior Vice President of Engineering, Dr. Nathan P. Lawrence, Vice President of Marketing and Sales, and Dr. Alexander Lazarev, Vice President of Research and Development make up the other members of the Senior Management team.

Mr. Alan Stone, Managing Director of WallStreet Research", added: "WSR is very impressed with Pressure BioSciences' management; current business strategy; recent milestone accomplishments, including the release of enhanced products, successful close of $4M in new equity financing, and strong product endorsement from worldwide Key Opinion Leaders; and their significantly improved financial results in the three and nine month periods ended September 30, 2015. We strongly believe that at current levels PBIO is highly undervalued, and that their current position in the market presents a great potential for accelerated revenue growth leading to potential value creation. WSR has followed the company for several years prior to initiating corporate profile coverage."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.

About WallStreet Research"

WallStreet Research" ("WSR") is a prominent research boutique led by Mr. Alan Stone, Managing Director of Alan Stone & Company, LLC (ASC). The firm specializes in the microcap and small cap investment arena, looking for emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength, and outstanding long-term earnings growth possibilities. Mr. Stone was formerly a securities analyst and assistant portfolio manager at Merrill Lynch Asset Management, an investment analyst at Prudential Insurance Company's Capital Markets Group, and an investment banker with Ladenburg Thalmann & Company. The firm has offices in Los Angeles, CA, Palm Beach, FL, and New York City, NY, and is well known for discovering undervalued companies and bringing them to the attention of the investment community. ASC/WSR also arranges road shows for its publicly traded clients, before the investment community in New York City, California and Florida.

Disclaimer

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to he accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. The featured company will pay a fee of $7000 in cash to Alan Stone & Company LLC for preparation and distribution of this profile, including other potential fees associated with various consulting and investor relations' services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.

Contact / Source:

WallStreet Research"
Alan Stone
310-444-3940
[email protected]

Barbara Blake
415-419-4239
[email protected]

www.WallStreetResearch.org
www.SouthFloridaInvestmentForum.com
www.SouthernCaliforniaInvestmentForum.com

Source: WallStreet Research

You May Also Be Interested In

• Vaxxinity, Inc (VAXX) to Voluntarily Delist
• ZW Data Action Technologies (CNET) Receives Nasdaq Non-compliance Notice
• Bio-Path Holdings (BPTH) Announces 375K Share Offering at $3.225/sh